Other formats:
BibTeX
LaTeX
RIS
@article{1371693,
author = {Mocikova, Heidi and Pytlik, Robert and Sykorova, Alice and Janíková, Andrea and Prochazka, Vit and Vokurka, Samuel and Berkova, Adela and Belada, David and Campr, Vit and Buresova, Lucie and Trneny, Marek},
article_location = {London},
article_number = {12},
doi = {http://dx.doi.org/10.3109/10428194.2016.1167203},
keywords = {Chemotherapy; primary central nervous system lymphoma; rituximab},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & Lymphoma},
title = {Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry},
volume = {57},
year = {2016}
}
TY - JOUR
ID - 1371693
AU - Mocikova, Heidi - Pytlik, Robert - Sykorova, Alice - Janíková, Andrea - Prochazka, Vit - Vokurka, Samuel - Berkova, Adela - Belada, David - Campr, Vit - Buresova, Lucie - Trneny, Marek
PY - 2016
TI - Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry
JF - Leukemia & Lymphoma
VL - 57
IS - 12
SP - 2777-2783
EP - 2777-2783
PB - Informa Healthcare
SN - 10428194
KW - Chemotherapy
KW - primary central nervous system lymphoma
KW - rituximab
N2 - We have investigated whether the addition of rituximab to methotrexate, procarbazine, vincristine, radiotherapy and cytarabine was associated with improved outcome of primary central nervous system lymphomas (PCNSL). Of 164 patients, 49 received rituximab. Median age was 63 years, median Karnofsky performance score (KPS) was 60 and median follow-up of living patients was 59.5 months. 1- and 2-year PFS were 49.7 and 37.9%, 1- and 2-year OS were 57.0 and 453%. Median progression-free survival (PFS), but not overall survival (OS) was significantly better for patients treated with rituximab (22.9 vs. 10.9 months, p = 0.037). In multivariate analysis, age <= 70 years and KPS >= 90 were predictive for PFS and OS, rituximab was an independent prognostic factor for PFS only. In landmark analyses, rituximab was not found beneficial for long-term survivors and no group particularly benefited from rituximab. In conclusion, addition of rituximab was associated with improved PFS, but not OS in this unselected cohort of PCNSL patients.
ER -
MOCIKOVA, Heidi, Robert PYTLIK, Alice SYKOROVA, Andrea JANÍKOVÁ, Vit PROCHAZKA, Samuel VOKURKA, Adela BERKOVA, David BELADA, Vit CAMPR, Lucie BURESOVA and Marek TRNENY. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, 2016, vol.~57, No~12, p.~2777-2783. ISSN~1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2016.1167203.
|
